A cannabinoid receptor 1 mutation proximal to the DRY motif results in constitutive activity and reveals intramolecular interactions involved in receptor activation

Activation of a G-protein-coupled receptor involves changes in specific microdomain interactions within the transmembrane region of the receptor. Here, we have focused on the role of L207, proximal to the DRY motif of the human cannabinoid receptor 1 in the interconversion of the receptor resting and active states. Ligand binding analysis of the mutant receptor L207A revealed an enhanced affinity for agonists (three- to six-fold) and a diminished affinity for inverse agonists (19- to 35-fold) compared to the wild-type receptor, properties characteristic of constitutive activity. To further examine whether this mutant adopts a ligand-independent, active form, treatment with GTPgammaS was used to inhibit G protein coupling. Under these conditions, the L207A receptor exhibited a 10-fold increase in affinity for the inverse agonist SR141716A, consistent with a shift away from an enhanced precoupled state. Analysis of the cellular activity of the L207A receptor showed elevated basal cyclic AMP accumulation relative to the wild type that is inhibited by SR141716A, consistent with receptor-mediated Gs precoupling. Using toxins to selectively abrogate Gs or Gi coupling, we found that CP55940 nonetheless induced only a Gi response suggesting a strong preference of this ligand-bound form for Gi in this system. Molecular dynamics simulations reveal that the single residue change of L207A impacts the association of TM3 and TM6 in the receptor by altering hydrophobic interactions involving L207, the salt bridge involving the Arg of the DRY motif, and the helical structure of TM6, consistent with events leading to activation. The structural alterations parallel those observed in models of a mutant CB(1) receptor T210I, with established constitutive activity (D'Antona, A.M., Ahn, K.H. and Kendall, D.A., 2006. Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. Biochemistry, 45, 5606-5617).

[1]  A. Scheer,et al.  Constitutively active mutants of the alpha 1B‐adrenergic receptor: role of highly conserved polar amino acids in receptor activation. , 1996, The EMBO journal.

[2]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[3]  K. Mackie,et al.  Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Neubig,et al.  Gi Activator Region of α2A-Adrenergic Receptors: Distinct Basic Residues Mediate Gi versus Gs Activation , 1999 .

[5]  V. Watts,et al.  D2 Dopamine Receptors Modulate Gα-Subunit Coupling of the CB1 Cannabinoid Receptor , 2004, Journal of Pharmacology and Experimental Therapeutics.

[6]  Mary E Abood,et al.  An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. , 2003, Journal of medicinal chemistry.

[7]  R. Graham,et al.  Constitutive activation of a single effector pathway: evidence for multiple activation states of a G protein-coupled receptor. , 1996, Molecular pharmacology.

[8]  Z. Vogel,et al.  Cannabinoid Receptor Activation Differentially Regulates the Various Adenylyl Cyclase Isozymes , 1998, Journal of neurochemistry.

[9]  P. Casellas,et al.  A Selective Inverse Agonist for Central Cannabinoid Receptor Inhibits Mitogen-activated Protein Kinase Activation Stimulated by Insulin or Insulin-like Growth Factor 1 , 1997, The Journal of Biological Chemistry.

[10]  D. Kendall,et al.  Involvement of the Carboxyl Terminus of the Third Intracellular Loop of the Cannabinoid CB1 Receptor in Constitutive Activation of Gs , 1999, Journal of neurochemistry.

[11]  D. Cassel,et al.  Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Zuscik,et al.  Identification of a Conserved Switch Residue Responsible for Selective Constitutive Activation of the β2-Adrenergic Receptor* , 1998, The Journal of Biological Chemistry.

[13]  M. Glass,et al.  Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. , 1999, Molecular pharmacology.

[14]  Francesca Fanelli,et al.  Mutagenesis and modelling of the alpha(1b)-adrenergic receptor highlight the role of the helix 3/helix 6 interface in receptor activation. , 2002, Molecular pharmacology.

[15]  A unique constitutively activating mutation in third transmembrane helix of luteinizing hormone receptor causes sporadic male gonadotropin-independent precocious puberty. , 1998, The Journal of clinical endocrinology and metabolism.

[16]  A. Howlett,et al.  Chemically Distinct Ligands Promote Differential CB1 Cannabinoid Receptor-Gi Protein Interactions , 2005, Molecular Pharmacology.

[17]  F. Ehlert,et al.  Signaling through the muscarinic receptor-adenylate cyclase system of the heart is buffered against GTP over a range of concentrations. , 1990, Molecular pharmacology.

[18]  Q. Yang,et al.  Influence of G protein type on agonist efficacy. , 1999, Molecular pharmacology.

[19]  M. Debatis,et al.  Phospholipase participation in cannabinoid-induced release of free arachidonic acid. , 1994, Biochemical pharmacology.

[20]  M. Scheinin,et al.  Constitutive precoupling to Gi and increased agonist potency in the α2B-adrenoceptor , 2003 .

[21]  A. Howlett.  Efficacy in CB1 receptor‐mediated signal transduction , 2004, British journal of pharmacology.

[22]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2002, Chembiochem : a European journal of chemical biology.

[23]  Christopher A Reynolds,et al.  Toward the active conformations of rhodopsin and the β2‐adrenergic receptor , 2004, Proteins.

[24]  A. Makriyannis,et al.  Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. , 1998, Journal of medicinal chemistry.

[25]  R. Lefkowitz,et al.  A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. , 1993, The Journal of biological chemistry.

[26]  Marcus Elstner,et al.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.

[27]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[28]  O. Lichtarge,et al.  C5a Receptor Activation , 1999, The Journal of Biological Chemistry.

[29]  A. Scheer,et al.  Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation. , 2000, Molecular pharmacology.

[30]  E. sanders-Bush,et al.  Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands. , 1994, The Journal of biological chemistry.

[31]  Xuebo Liu,et al.  Mutations That Induce Constitutive Activation and Mutations That Impair Signal Transduction Modulate the Basal and/or Agonist-stimulated Internalization of the Lutropin/Choriogonadotropin Receptor* , 1998, The Journal of Biological Chemistry.

[32]  Bryan L Roth,et al.  Evidence for a Model of Agonist-induced Activation of 5-Hydroxytryptamine 2A Serotonin Receptors That Involves the Disruption of a Strong Ionic Interaction between Helices 3 and 6* 210 , 2002, The Journal of Biological Chemistry.

[33]  G Vassart,et al.  Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.

[34]  M. Herkenham,et al.  International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors , 2002, Pharmacological Reviews.

[35]  J. Murphy,et al.  The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. , 1999, The Journal of pharmacology and experimental therapeutics.

[36]  D. Kendall,et al.  Ligand Binding and Modulation of Cyclic AMP Levels Depend on the Chemical Nature of Residue 192 of the Human Cannabinoid Receptor 1 , 1998, Journal of neurochemistry.

[37]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[38]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[39]  A. Howlett,et al.  Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. , 1984, Molecular pharmacology.

[40]  A. Howlett,et al.  Differential receptor-G-protein coupling evoked by dissimilar cannabinoid receptor agonists. , 1998, Cellular signalling.

[41]  H. Weinstein,et al.  Ligand-induced domain motion in the activation mechanism of a G-protein-coupled receptor. , 1994, Protein engineering.

[42]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[43]  D. Mierke,et al.  Characterization of the molecular motions of constitutively active G protein-coupled receptors for parathyroid hormone. , 2001, Biophysical chemistry.

[44]  J. Ballesteros,et al.  Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6* , 2001, The Journal of Biological Chemistry.

[45]  J. Baldwin,et al.  An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. , 1997, Journal of molecular biology.

[46]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[47]  S. McAllister,et al.  Structural Mimicry in Class A G Protein-coupled Receptor Rotamer Toggle Switches , 2004, Journal of Biological Chemistry.

[48]  D. Kendall,et al.  Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. , 2003, Biochemical pharmacology.

[49]  P. Leff,et al.  Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. , 1998, Molecular pharmacology.

[50]  K. Mackie,et al.  Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. , 1995, Molecular pharmacology.

[51]  U. Gether.  Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[52]  P. Leff,et al.  A Three‐State Receptor Model: Predictions of Multiple Agonist Pharmacology for the Same Receptor Type a , 1998, Annals of the New York Academy of Sciences.

[53]  M. Glass,et al.  Concurrent Stimulation of Cannabinoid Cb1 and Dopamine D2 Receptors Augments Camp Accumulation in Striatal Neurons: Evidence for a G S Linkage to the Cb1 Receptor , 1997 .

[54]  K. Ahn,et al.  Mutations of CB1 T210 produce active and inactive receptor forms: correlations with ligand affinity, receptor stability, and cellular localization. , 2006, Biochemistry.